CPT® Code 87913

Official Description

Infectious agent genotype analysis by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), mutation identification in targeted region(s)

Common Language Description

Infectious agent genotype analysis by nucleic acid, specifically for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), involves the identification of mutations within targeted regions of the virus's genetic material. This process is crucial for understanding the evolution and transmission dynamics of the virus, particularly in the context of the ongoing coronavirus disease (COVID-19) pandemic. Genotyping SARS-CoV-2 isolates allows researchers and healthcare professionals to monitor genetic variations that may impact the virus's behavior, including its transmissibility and potential resistance to vaccines. The analysis is particularly relevant for patients who have contracted COVID-19 despite being fully vaccinated, as it helps in identifying any mutations that may contribute to vaccine escape. The procedure typically begins with a specimen collected from a nasopharyngeal swab, which is tested for the presence of SARS-CoV-2 RNA. Following this, the viral nucleic acid is extracted and purified, setting the stage for reverse transcription polymerase chain reaction (RT-PCR) testing. This sophisticated technique involves converting the viral RNA into complementary DNA (cDNA) and amplifying it to detect specific genetic markers. The use of labeled DNA probes during the hybridization process enables the identification of nucleotide base substitutions, which are critical for determining the genetic profile of the virus and understanding its potential implications for public health and vaccine efficacy.

1. Indications

COVID-19 Infection This procedure is indicated for patients who have contracted COVID-19, particularly those who have been fully vaccinated, to identify any mutations in the SARS-CoV-2 virus that may affect transmission and vaccine efficacy.

Monitoring Virus Evolution Genotyping is essential for tracking the evolution of the SARS-CoV-2 virus, allowing for timely public health responses to emerging variants.

Vaccine Development The analysis of genetic variants is critical for vaccine development, as it helps in understanding how mutations may impact vaccine effectiveness.

2. Procedure

Step 1: Specimen Collection The procedure begins with the collection of a specimen from a nasopharyngeal swab. This sample is crucial as it contains the viral RNA necessary for subsequent testing.

Step 2: RNA Testing The collected specimen is tested for the presence of SARS-CoV-2 RNA. A positive result indicates the presence of the virus, which is essential for proceeding with the genotyping analysis.

Step 3: Nucleic Acid Extraction and Purification Following a positive RNA test, the viral nucleic acid is extracted and purified from the specimen. This step is vital to ensure that the nucleic acid is free from contaminants that could interfere with the testing process.

Step 4: Reverse Transcription The purified RNA is then subjected to reverse transcription, where it is converted into complementary DNA (cDNA) using the enzyme reverse transcriptase. This conversion is a critical step as it prepares the viral genetic material for amplification.

Step 5: Polymerase Chain Reaction (PCR) Amplification The cDNA undergoes exponential amplification through polymerase chain reaction (PCR). This process increases the quantity of the target DNA, making it easier to analyze.

Step 6: Probe Hybridization During the hybridization phase, a labeled fragment of DNA is introduced to bind to the target DNA sequences. This step forms probe-analyte hybrids, which are essential for detecting specific nucleotide base substitutions in the viral genome.

Step 7: Genotyping The pairing of the probes with the target DNA sequences allows for the identification of genetic variants. The pattern of nucleotide substitutions detected during this process enables presumptive genotyping of the SARS-CoV-2 virus.

3. Post-Procedure

After the genotyping analysis is completed, the results are interpreted to identify any mutations present in the SARS-CoV-2 virus. These findings can provide valuable insights into the virus's transmission dynamics and potential resistance to vaccines. Healthcare providers may use this information to inform treatment decisions and public health strategies. Additionally, ongoing monitoring of viral mutations is essential for adapting vaccine formulations and public health responses as the virus evolves. Patients may be advised on any necessary follow-up actions based on the results of the genotyping analysis.

Short Descr	NFCT AGT GNTYP ALYS SARSCOV2
Medium Descr	NFCT AGENT GENOTYPE ALYS NUCLEIC ACID SARSCOV2
Long Descr	Infectious agent genotype analysis by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]), mutation identification in targeted region(s)
Status Code	Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	09 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
CLIA Waived (QW)	No
APC Status Indicator	Service Paid under Fee Schedule or Payment System other than OPPS
Type of Service (TOS)	5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS)	none
MUE	2

XU	Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service
59	Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25.
76	Repeat procedure or service by same physician or other qualified health care professional: it may be necessary to indicate that a procedure or service was repeated by the same physician or other qualified health care professional subsequent to the original procedure or service. this circumstance may be reported by adding modifier 76 to the repeated procedure or service. note: this modifier should not be appended to an e/m service.
GW	Service not related to the hospice patient's terminal condition